Oric Pharmaceuticals
ORIC
7.36
-0.34
-4.42%
Oric Pharmaceuticals
US · ORIC
#3089 by market cap
Listed 2020
7.36
-0.34
-4.42%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.SEC · 2025/10/4
-
Rating change
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27Market Newswire · 2026/8/10
-
Guggenheim Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $18Market Newswire · 2026/10/22
-
Rating change
J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/10/14
-
Company notice
Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.SEC · 2026/1/7
-
Company notice
Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.SEC · 2026/1/7
-
Rating change
Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2026/6/29
-
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $27Market Newswire · 2026/10/27
-
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/10/30
-
Rating change
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27Benzinga · 2026/8/10
-
Company notice
Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.SEC · 2026/10/3
-
Rating change
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $18Market Newswire · 2026/10/26
-
Rating change
BTIG Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $26Market Newswire · 2026/10/26
-
Insiders Sold ORIC Pharmaceuticals At US$12.02, Meanwhile Stock Sits Near US$7.86Simply Wall St · 2026/11/14
-
Rating change
J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $23Market Newswire · 2026/8/7
-
Rating change
BTIG Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $26Market Newswire · 2026/9/23
-
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $25 to $27Market Newswire · 2026/10/28
-
Company notice
Oric Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Heyman Richard A.SEC · 2026/1/21
-
Rating change
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25Market Newswire · 2026/8/5
-
Rating change
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/10/23
-
Rating change
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/6/24
-
Rating change
Wells Fargo Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/6/11
-
Rating change
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15Market Newswire · 2026/6/3
-
Rating change
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)TipRanks · 2026/6/3
-
Rating change
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price TargetBenzinga · 2026/6/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Oric Pharmaceuticals discussion 0 comments